Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications
Expert Review of Clinical Pharmacology · 2023
DOI: 10.1080/17512433.2023.2232302 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Elisabeth Amadeo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Biliary tract carcinoma (BTC) is a heterogenous group of aggressive hepatic malignancies, second to hepatocellular carcinoma per prevalence. Despite clinical research advancement, the overall 5-year survival rate is just above 2%. With the identification of somatic core mutations in half of cholangiocarcinomas. In the intrahepatic subtype (iCCA), it is possible to target mutational pathways of pharmacological interest. AREAS COVERED: Major attention has been drawn to fibroblast growth factor receptor (FGFR), especially the type 2 (FGFR2), found mutated in 10-15% of iCCAs. FGFR2 fusions became the target of novel tyrosine-kinase inhibitors investigated in clinical studies, showing promising results so as to gain regulatory approval by American and European committees in recent years. Such drugs demonstrated a better impact on the quality of life compared to standard chemotherapy; however, side effects including hyperphosphatemia, gastrointestinal, eye, and nail disorders are common although mostly manageable. EXPERT OPINION: As FGFR inhibitors may soon become the new alternative to standard chemotherapy in FGFR-mutated cholangiocarcinoma, accurate molecular testing and monitoring of acquired resistance mechanisms will be essential. The possible application of FGFR inhibitors in first-line treatment, as well as in combination with current standard treatments, remains the next step to be taken.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
ORCID-Profile: Mara Persano, Andrea Casadei-Gardini
Zitieren
APA
Amadeo, E., Rossari, F., Vitiello, F., Burgio, V., Persano, M., Cascinu, S., Casadei-Gardini, A., & Rimini, M. (2023). Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2232302
Vancouver
Amadeo E, Rossari F, Vitiello F, Burgio V, Persano M, Cascinu S, et al. Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2232302
BibTeX
@article{Amadeo2023,
author = {Amadeo, Elisabeth and Rossari, Federico and Vitiello, Francesco and Burgio, Valentina and Persano, Mara and Cascinu, Stefano and Casadei-Gardini, Andrea and Rimini, Margherita},
title = {Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
doi = {10.1080/17512433.2023.2232302}
}
EUVIMED